<?xml version="1.0" encoding="UTF-8"?>
<AssessmentQuestion xmlns="http://soap.sforce.com/2006/04/metadata">
    <assessmentQuestionVersion>
        <isActive>true</isActive>
        <name>Mecasermin_InitialRenewal_COVERAGE_CRITERIA_Q1</name>
        <optionSourceResponseValue>false</optionSourceResponseValue>
        <questionText>Initiation criteria
1. Treatment can be initiated in patients who are at least two years of age and in whom epiphyseal closure has not yet occurred, and
with confirmed diagnosis of SPIGFD, defined by:
1.1. The patient has a known genetic mutation recognized as a cause of SPIGFD and/or
1.2. The patient has clinical and biochemical features of SPIGFD.
Discontinuation Criteria
1. Treatment with mecasermin must be discontinued upon the occurrence of any of the following:
1.1. Height velocity is less than 1 cm per 6 months or less than 2 cm per year, or
1.2. Bone age is more than 16 years in boys and 14 years in girls.
Prescribing Conditions
1. The patient must be under the care of a pediatric endocrinologist.
2. Mecasermin must not be prescribed concomitantly with recombinant GH treatment.</questionText>
        <status>Active</status>
        <versionNumber>1</versionNumber>
    </assessmentQuestionVersion>
    <dataType>TextBlock</dataType>
    <developerName>Mecasermin_InitialRenewal_COVERAGE_CRITERIA_Q1</developerName>
    <name>Mecasermin_InitialRenewal_COVERAGE_CRITERIA_Q1</name>
    <questionCategory>Demographic</questionCategory>
</AssessmentQuestion>
